Cargando…
PA01.69. Immunological and virological effect of amrita tablate in human immunodeficiency virus positive patients
PURPOSE: To assess the safety and efficacy of Amrita tablets in human immunodeficiency virus positive patients. METHOD: The randomized double blind placebo controlled trial carried out 40 HIV positive patients at Ayurvedic Drug Research Institute Motihari Bihar, with permission from Institutional Et...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800873/ |
Sumario: | PURPOSE: To assess the safety and efficacy of Amrita tablets in human immunodeficiency virus positive patients. METHOD: The randomized double blind placebo controlled trial carried out 40 HIV positive patients at Ayurvedic Drug Research Institute Motihari Bihar, with permission from Institutional Ethic Committee for achieve the purpose. Out of 40 HIV patients 30 were male and 10 patients of female. The HIV positive patients were randomly assigned to three groups A, B and C. Group A received Amrita tablet. Group B received Amritasava and group C received Placebo. The doses of Amrita tablet, two tabs. And Amritasava 10ml with one cup water twice daily for six months. The hematological investigation was repeated at the end of the study. RESULT: In study participants, HIV was more common in the 15 30 year's age group. Half of the enrolled patients where from the age group 42% from 30 40 years and 8% from 40 50 age group. It was observed the end of trial period of amrita tablet was marked increase in the number of CD4count and viral load reduced<300 copies/ml. It was also found gradual reduction of clinical feature of early symptomatic stage of HIV disease. Among the participants received Amritasava there was moderate increase in the number of CD4 count, but there was no difference in viral load. Participants was received placebo there was no differences in CD4 count before the six months. CONCLUSION: Amrita tab. is an ideal herbal formulation. It contain mainly standardchemically defined Asava of Amrita (Tinospora cardifolia) ashwagandha (Withania somnifera) and yasthimadhu (Glycyrrhiza glabra). It increases in number of CD4 count and reduce viral load. It is safe and no adverse toxic effect on long therapy. Now it is necessary to evaluate the physiological activity, pharmacological property toxicity and determination of structure of amrita tab. To antiretroviral classes of drug for used in the health care systems of countries with in the Region and elsewhere in the world. |
---|